Discussion {#onco12611-sec-0006}
==========

BTCs are highly aggressive with poor prognosis and few treatment options following progression on gemcitabine‐cisplatin chemotherapy. Preclinical evidence suggests that simultaneous blockade of VEGFR‐2 and PD‐1 or PD‐L1 induces additive antitumor effects \[[1](#onco12611-bib-0001){ref-type="ref"}\], \[[2](#onco12611-bib-0002){ref-type="ref"}\], \[[3](#onco12611-bib-0003){ref-type="ref"}\]. This is the first study to combine an antiangiogenic agent (ramucirumab, an IgG1 VEGFR‐2 antagonist) with an immune checkpoint inhibitor (pembrolizumab, an IgG4 PD‐1 antagonist) to simultaneously target both processes in patients with previously treated advanced BTC.

Twenty‐six patients received at least one dose of ramucirumab and pembrolizumab. Baseline demographics and characteristics were as expected for an advanced, previously treated population. The majority of patients had intrahepatic (42.3%) or extrahepatic (34.6%) cholangiocarcinoma. Median therapy duration was 9 weeks with ramucirumab and 9.3 weeks with pembrolizumab. Median follow‐up duration was 15.7 (95% confidence interval \[CI\] 10.3--17.0) months.

TRAEs occurred in most patients and were predominantly of grade 1--2 severity. The most frequently reported TRAEs (any grade) were fatigue, hypertension, nausea, diarrhea, and hypothyroidism. Nine (34.6%) patients experienced a grade 3 TRAE. One patient experienced grade 4 treatment‐related neutropenia. Serious adverse events (AEs) were reported for 15 (57.7%) patients; these were deemed related to treatment by the investigator in seven (26.9%) patients. One patient discontinued treatment due to treatment‐related elevation of transaminases. There were no treatment‐related deaths.

Reduction in tumor size from baseline in target lesions was observed in 9 (37.5%) of 24 patients; two patients were not evaluable due to no postbaseline tumor assessment (Fig. [1](#onco12611-fig-0001){ref-type="fig"}). One (3.8%) patient had a partial response, nine (34.6%) had stable disease, and 13 (50%) had progressive disease as their best response to treatment. Disease control occurred in 10 (38.5%) patients; median duration of stable disease was 3.9 months. Median PFS was 1.6 months. Median PFS in patients with PD‐L1‐positive (*n* = 12) and ‐negative (*n* = 12) tumors was 1.5 months and 1.6 months, respectively. Limited analyses of efficacy by primary tumor site and line of therapy did not demonstrate any clear trends. Median OS was 6.4 months. Median OS in patients with PD‐L1‐positive and ‐negative tumors was 11.3 months and 6.1 months, respectively. One patient remained on treatment. Of the seven (26.9%) patients who received postdiscontinuation systemic anticancer therapy, six were PD‐L1 positive and one was PD‐L1 negative. Although the chemotherapy‐free combination in our study reported a tolerable toxicity profile, ramucirumab plus pembrolizumab did not demonstrate an improvement in survival when compared with historical controls in biomarker‐unselected, heavily pretreated patients with advanced or metastatic BTC.

![Maximum change in tumor size from baseline.\
Abbreviation: PD‐L1, programmed death‐ligand 1.](onco12611-fig-0001){#onco12611-fig-0001}

Trial Information {#onco12611-sec-0007}
=================

**Disease**Biliary tract: gallbladder cancer and cholangiocarcinoma**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**1--2 prior regimens**Type of Study ‐ 1**Phase I**Primary Endpoint**Safety and tolerability**Secondary Endpoint**Progression‐free survival, overall survival, objective response rate, disease control rate, duration of response, time to response, and pharmacokinetics of ramucirumab**Additional Details of Endpoints or Study Design** Phase I, multicohort, nonrandomized, open‐label study. Patients ≥18 years of age were eligible for enrollment if they had histologically or cytologically confirmed biliary tract adenocarcinoma (gallbladder, intrahepatic and extrahepatic cholangiocarcinoma, or ampulla of Vater); unresectable, recurrent, or metastatic disease extent; and progression on 1--2 lines of prior chemotherapy or biological therapy. Prior therapy for advanced disease must have included gemcitabine and cisplatin. Prior therapy in an adjuvant or neoadjuvant setting was not considered a prior line of systemic chemotherapy, unless the patient had rapidly progressed, as defined by there having been ≤6 months since the last dose of chemotherapy. Furthermore, patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, measurable disease (RECIST; version 1.1), adequate organ function, and baseline tumor tissue for biomarker analysis. PD‐L1 expression was assessed using a provisional cutoff by immunohistochemistry with an investigational version of the PD‐L1 IHC 22C3 pharmDx (Agilent, Carpinteria, CA). The "combined positive score" (CPS) is the number of staining tumor and immune cells relative to total tumor cells. PD‐L1 status was classified by using CPS as positive (≥1%) or negative (\<1%) for biliary tract cancer \[[4](#onco12611-bib-0004){ref-type="ref"}\]. The trial adhered to the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, and applicable local regulations. The protocol was approved by the ethics committees of all participating centers, and all patients provided written informed consent before study entry. Tumor response was assessed radiographically by the investigator at baseline, every 6 weeks (±7 days) after date of first study treatment for the first 24 weeks, and then every 12 weeks (±7 days) thereafter. Confirmation of partial or complete response was required at the next scheduled assessment, 6 weeks (±7 days) later. If radiographic assessment indicated progressive disease, a confirmatory assessment was required at least 4 weeks later; patients could continue receiving study treatment during this period. Study treatment was to be discontinued if the repeat scan confirmed progression. Following discontinuation, patients were followed up for survival every 90 days. Safety was assessed and graded throughout the study and for 30 days after treatment discontinuation. AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, and judged by the investigator to be related or nonrelated to study treatment. The study planned to enroll approximately 25--30 patients. The sample size was selected to allow adequate assessment of safety at the recommended doses for ramucirumab and pembrolizumab. The exact binomial test was used in the power analysis: Assuming a 10%--15% increase between the null and target response rate, and the target treatment effect on ORR is between 20% and 30%, a sample size of 25--30 will provide approximately 60%--80% power with a one‐sided α level of 0.20. Data cutoff for the current analysis was February 1, 2018. Other disease cohorts from this same trial (NCT02443324) will be published separately. **Investigator\'s Analysis**Manageable safety profile with limited clinical activity

Drug Information {#onco12611-sec-0008}
================

Drug 1 Generic/Working NameRamucirumabTrade NameCyramzaCompany NameEli Lilly and CompanyDrug TypeAntibodyDrug ClassAntiangiogenic: anti‐VEGFR‐2Dose8 mg/kgRouteIVSchedule of AdministrationRamucirumab days 1 and 8 every 3 weeks until disease progression or other discontinuation criteria met.Drug 2 Generic/Working NamePembrolizumabTrade NameKeytrudaCompany NameMerck and Co., Inc.Drug TypeAntibodyDrug ClassImmunotherapy: anti‐PD‐1Dose200 mg per flat doseRouteIVSchedule of AdministrationPembrolizumab day 1 every 3 weeks until disease progression or other discontinuation criteria met.

Patient Characteristics for Phase I Experimental {#onco12611-sec-0009}
================================================

Number of Patients, Male8Number of Patients, Female18StageNonresectable, recurrent, or metastaticAgeMedian (range): 63 (36--78)Number of Prior Systemic TherapiesMedian (range): 1 (1--3)Performance Status: ECOG0 --- 121 --- 14OtherComplete baseline demographic and disease characteristics are presented in Table [1](#onco12611-tbl-0001){ref-type="table"}

Primary Assessment Method {#onco12611-sec-0010}
=========================

TitleTotal patient populationNumber of Patients Screened33Number of Patients Enrolled26Number of Patients Evaluable for Toxicity26Number of Patients Evaluated for Efficacy26Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 1 (4%)Response Assessment SD*n* = 9 (35%)Response Assessment PD*n* = 13 (50%)Response Assessment OTHER*n* = 3 (12%)(Median) Duration Assessments PFS1.64 months, CI: 1.38--2.76(Median) Duration Assessments OS6.44 months, CI: 4.17--13.27(Median) Duration Assessments Response Duration6 monthsOutcome NotesFurther graphical details on maximum change in tumor size over time, duration of treatment, and efficacy results by PD‐L1 status are presented in the extended discussion.

Adverse Events {#onco12611-sec-0011}
==============

imageJohn Wiley & Sons, Ltd.[^2][^3][^4][^5]

Serious Adverse Events {#onco12611-sec-0012}
======================

imageJohn Wiley & Sons, Ltd.

Assessment, Analysis, and Discussion {#onco12611-sec-0013}
====================================

CompletionStudy completed; one patient remains on study treatment.Investigator\'s AssessmentManageable safety profile with limited clinical activity

 {#onco12611-sec-0113}

Biliary tract cancer (BTC) arises from the epithelial lining of the gallbladder, intrahepatic and extrahepatic bile ducts, and ampulla of Vater. There are more than 186,000 new cases of BTC diagnosed worldwide each year \[[5](#onco12611-bib-0005){ref-type="ref"}\]. The incidence of BTC is increasing in the U.S. and some European countries, largely due to an increase in diagnosis of intrahepatic cholangiocarcinoma \[[6](#onco12611-bib-0006){ref-type="ref"}\], \[[7](#onco12611-bib-0007){ref-type="ref"}\]. Lymph node involvement and distance metastases are early characteristics of BTC, preventing up to 90% of patients from receiving curative intent surgery \[[8](#onco12611-bib-0008){ref-type="ref"}\].

Gemcitabine in combination with cisplatin is standard first‐line palliative treatment for advanced BTC, with a median overall survival (OS) of 11.2--11.7 months \[[9](#onco12611-bib-0009){ref-type="ref"}\], \[[10](#onco12611-bib-0010){ref-type="ref"}\]. There is no established standard of care following progression on gemcitabine‐cisplatin, and chemotherapeutic agents have modest activity in this setting. A recent systematic review that included 14 phase II trials indicated an objective response rate of 7.7%, mean progression‐free survival (PFS) of 3.2 months, and mean OS of 7.2 months with second‐line therapy \[[11](#onco12611-bib-0011){ref-type="ref"}\]. Outcomes are suboptimal, and a substantial unmet need persists to improve outcomes for patients with advanced BTC.

Antiangiogenic therapies have several noted immunostimulatory effects including increased trafficking of T cells into tumors as well as reduction of immunosuppressive cytokines and T regulatory cells, suggesting antiangiogenic therapies may complement subsequent or concurrent immunostimulatory therapies \[[1](#onco12611-bib-0001){ref-type="ref"}\], \[[2](#onco12611-bib-0002){ref-type="ref"}\], \[[12](#onco12611-bib-0012){ref-type="ref"}\], \[[13](#onco12611-bib-0013){ref-type="ref"}\], \[[14](#onco12611-bib-0014){ref-type="ref"}\], \[[15](#onco12611-bib-0015){ref-type="ref"}\]. Despite reports of vascular endothelial growth factor and programmed death‐ligand 1 (PD‐L1) expression in a subset of patients with advanced BTC, there have been no published clinical studies combining an antiangiogenic agent with an immune checkpoint inhibitor in this patient population \[[16](#onco12611-bib-0016){ref-type="ref"}\], \[[17](#onco12611-bib-0017){ref-type="ref"}\], \[[18](#onco12611-bib-0018){ref-type="ref"}\], \[[19](#onco12611-bib-0019){ref-type="ref"}\], \[[20](#onco12611-bib-0020){ref-type="ref"}\], \[[21](#onco12611-bib-0021){ref-type="ref"}\], \[[22](#onco12611-bib-0022){ref-type="ref"}\]. Herein we report the combination of ramucirumab plus pembrolizumab in 26 patients revealed no unexpected safety findings, which is consistent with reports of other tumor cohorts within this trial (Fig. [2](#onco12611-fig-0002){ref-type="fig"}) \[[23](#onco12611-bib-0023){ref-type="ref"}\], \[[24](#onco12611-bib-0024){ref-type="ref"}\], \[[25](#onco12611-bib-0025){ref-type="ref"}\]. The most common toxic effects were of grade 1--2 severity and were manageable with supportive care alone or with dose reductions or delays, without substantial reduction in the planned dose intensity for either study drug (Table [2](#onco12611-tbl-0002){ref-type="table"}). Grade 3 treatment‐related adverse events, most commonly hypertension, were experienced by 9 (34.6%) of 26 patients.

PD‐L1 expression on tumor and immune cells has been associated with increased clinical benefit from programmed death 1 (PD‐1)‐ and PD‐L1‐targeted therapies in various tumor types \[[26](#onco12611-bib-0026){ref-type="ref"}\], \[[27](#onco12611-bib-0027){ref-type="ref"}\]. PD‐1 and PD‐L1 expression is upregulated in intrahepatic cholangiocarcinoma tumor tissues and was associated with both poor differentiation and stage, whereas increased CD8^+^ T cells in tumors was associated with better tumor differentiation \[[28](#onco12611-bib-0028){ref-type="ref"}\], \[[29](#onco12611-bib-0029){ref-type="ref"}\]. Bang et al. enrolled only PD‐L1‐positive advanced BTC patients in the KEYNOTE‐028 study and reported that 4 (17%) of 23 evaluable patients responded to pembrolizumab monotherapy \[[30](#onco12611-bib-0030){ref-type="ref"}\]. We did not restrict enrollment based on PD‐L1 status, and less than half (46.2%) of patients had tumors that scored positive for PD‐L1 expression, as defined by a combined positive score of ≥1% (Table [1](#onco12611-tbl-0001){ref-type="table"}). The only patient with an objective response in our study had extrahepatic cholangiocarcinoma that was positive for PD‐L1, a time to response of 2.7 months, and a total duration of response of 6.0 months (Table [3](#onco12611-tbl-0003){ref-type="table"}). Acknowledging limitations of cross‐trial comparison and sample size, baseline characteristics and demographics were similar between both studies with the exception of PD‐L1 status and ethnicity, with white as the majority in our study compared with Asian as the majority in the KEYNOTE‐028 study (Table [1](#onco12611-tbl-0001){ref-type="table"}) \[[30](#onco12611-bib-0030){ref-type="ref"}\]. At this time, it is unclear if differences in outcome and toxicity exist between Asian and white patients treated with an immune checkpoint inhibitor. A subset of patients in both studies had prolonged periods of disease stability (three patients in our study on treatment ≥38 weeks; Fig. [3](#onco12611-fig-0003){ref-type="fig"}A, [3](#onco12611-fig-0003){ref-type="fig"}B), highlighting the need to identify biomarkers that predict clinical efficacy of pembrolizumab and ramucirumab in advanced biliary tract cancers. Although no difference in median PFS was observed by PD‐L1 status (Fig. [4](#onco12611-fig-0004){ref-type="fig"}A), patients whose tumors were PD‐L1 positive had improved OS compared with those whose tumors were PD‐L1 negative in our study (Fig. [4](#onco12611-fig-0004){ref-type="fig"}B). The survival signal in PD‐L1‐positive patients is interesting, but we are limited by sample size and have no historical reference for the natural history of patients with PD‐L1 positivity relative to the wider population, and it may represent selection bias. Consistent with improved survival in PD‐L1‐positive patients, six of the seven patients who received postdiscontinuation systemic anticancer therapy were positive for PD‐L1 (Table [4](#onco12611-tbl-0004){ref-type="table"}).

In addition to PD‐L1 expression, high microsatellite instability (MSI‐H) has been reported to correlate with the clinical activity of PD‐1 and PD‐L1 inhibitors in multiple tumor types \[[31](#onco12611-bib-0031){ref-type="ref"}\], \[[32](#onco12611-bib-0032){ref-type="ref"}\], \[[33](#onco12611-bib-0033){ref-type="ref"}\]. The incidence of MSI‐H in biliary tract cancer has not been comprehensively studied but is reported to be infrequent, occurring in approximately 5% or lower each for gallbladder carcinoma and extrahepatic cholangiocarcinoma and 10% or lower each for intrahepatic cholangiocarcinoma and ampullary carcinoma \[[34](#onco12611-bib-0034){ref-type="ref"}\], \[[35](#onco12611-bib-0035){ref-type="ref"}\]. In the limited number of samples tested for MSI in our study, including the patient with an objective response, we did not observe any patients with MSI‐H. The MSI status has not been reported for KEYNOTE‐028.

In summary, ramucirumab plus pembrolizumab did not demonstrate an improvement in survival when compared with historical controls in biomarker‐unselected, heavily pretreated patients with advanced or metastatic BTC (Table [5](#onco12611-tbl-0005){ref-type="table"}; Fig. [5](#onco12611-fig-0005){ref-type="fig"}). However, median OS in patients with PD‐L1‐positive tumors is interesting, and additional biomarker data will guide the future development of this combination. Ramucirumab is concurrently being investigated in the phase II setting for advanced or metastatic BTC in combination with gemcitabine‐cisplatin for first‐line treatment (NCT02711553) and as monotherapy in patients previously treated with a gemcitabine‐based regimen (NCT02520141) \[[36](#onco12611-bib-0036){ref-type="ref"}\].

Figures and Tables {#onco12393-sec-6014}
==================

###### Baseline demographics and characteristics

![](onco12611-tbl-0001){#nlm-graphic-9}

Data are *n* (%) unless otherwise indicated.

A detailed summary of prior anticancer therapies is included in Table [5](#onco12611-tbl-0005){ref-type="table"}.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; PD‐L1, programmed death‐ligand 1.

![Consolidated Standards of Reporting Trials diagram.](onco12611-fig-0002){#onco12611-fig-0002}

###### Treatment duration

![](onco12611-tbl-0002){#nlm-graphic-15}

Abbreviation: IQR, interquartile range.

###### Confirmed efficacy results per RECIST v1.1

![](onco12611-tbl-0003){#nlm-graphic-17}

Abbreviations: CI, confidence interval; NR, not reported.

![Tumor response assessment per RECIST v1.1 by investigator review. **(A)**: Change in tumor size over time. **(B)**: Treatment duration and response.\
Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PD‐L1, programmed death‐ligand 1; PR, partial response; SD, stable disease.](onco12611-fig-0003){#onco12611-fig-0003}

###### Poststudy systemic anticancer therapy

![](onco12611-tbl-0004){#nlm-graphic-23}

![Kaplan‐Meier plot. **(A)**: Progression‐free survival. **(B)**: Overall survival.\
Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression‐free survival.](onco12611-fig-0004){#onco12611-fig-0004}

![Kaplan‐Meier plot. Progression‐free survival **(A)** and overall survival **(B)** by PD‐L1 status.\
Abbreviations: CI, confidence interval; PD‐L1, programmed death‐ligand 1.](onco12611-fig-0005){#onco12611-fig-0005}

###### Prior systemic anticancer therapy[a](#onco12611-note-0015){ref-type="fn"}

![](onco12611-tbl-0005){#nlm-graphic-33}

Data are *n* (%).

Patients may have received more than one type of therapy.

Abbreviation: IDH, isocitrate dehydrogenase.

This study was sponsored by Eli Lilly and Company, in collaboration with Merck & Co., Inc. We thank the patients, their families, and the study personnel across all sites for participating in this study. Writing assistance was provided by Eli Lilly and Company. Editorial assistance was funded by Eli Lilly and Company and provided by Teri Tucker (Syneos Health, Raleigh, NC).

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT02443324](https://clinicaltrials.gov/ct2/show/NCT02443324)

**Sponsors**: Eli Lilly and Company in collaboration with Merck & Co., Inc.

**Principal Investigator**: Roy S. Herbst

**IRB Approved**: Yes

[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).

Disclosures {#onco12611-sec-0015}
===========

**Roy S. Herbst**: Merck, Eli Lilly & Co. (RF, H); **Richard A Walgren**: Eli Lilly & Co. (E, OI); Ryan C Widau: Eli Lilly & Co. (E, OI);**Emiliano Calvo**: Novartis, Nanobiotix, Janssen‐Cilag, PsiOxus Therapeutics, Seattle Genetics, EUSA Pharma, Abbvie, Celgene, AstraZeneca, Guidepoint Global, Roche/Benentech, GLG, Pfizer, Servier, Amcure (C/A), AstraZeneca, Novartis, BeiGene, START (RF), START, HM Hospitales Group (E), HM Hospitales Group (H), START, Oncoart Associated, International Cancer Consultants (OI), Novartis (other: Speakers\' Bureau), Roche/Genentech (other: travel expenses), INTHEOS (other: President and Founder of the foundation, Investigational Therapeutics in Oncological Sciences); **Gu Mi**: Eli Lilly & Co. (E, OI); **Jin Jin**: Eli Lilly & Co. (E, OI); **David Ferry**: Eli Lilly & Co. (E, OI);**Ian Chau**: Sanofi Oncology, Eli‐Lilly, Bristol Meyers Squibb, MSD, Bayer, Merck‐Serono, Roche, Five Prime Therapeutics (C/A), Janssen‐Cilag, Sanofi Oncology, Merck‐Serono (RF), Taiho, Pfizer, Amgen, Eli‐Lilly (H). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board
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[^2]: Data are *n* (%). The table shows treatment‐related adverse events occurring in at least two patients, according to preferred term or consolidated category.

[^3]: Consolidated category (fatigue and asthenia).

[^4]: Consolidated category (rash and maculopapular rash).

[^5]: Abbreviation: ---, indicates a grade is not available per National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
